Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients

被引:139
作者
Xue, Jianmin [1 ]
Kass, Daniel J. [1 ]
Bon, Jessica [1 ]
Vuga, Louis [1 ]
Tan, Jiangning [1 ]
Csizmadia, Eva [2 ]
Otterbein, Leo [2 ]
Soejima, Makoto [1 ]
Levesque, Marc C. [1 ]
Gibson, Kevin F. [1 ]
Kaminski, Naftali [1 ]
Pilewski, Joseph M. [1 ]
Donahoe, Michael [1 ]
Sciurba, Frank C. [1 ]
Duncan, Steven R. [1 ]
机构
[1] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Surg, Sch Med, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE-DISEASE; LUNG-TISSUE; T-CELLS; ANTIBODY; RITUXIMAB; EXPRESSION; SERA; AUTOANTIBODIES; IDENTIFICATION;
D O I
10.4049/jimmunol.1203476
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We hypothesized B cells are involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive, restrictive lung disease that is refractory to glucocorticoids and other nonspecific therapies, and almost invariably lethal. Accordingly, we sought to identify clinically associated B cell-related abnormalities in these patients. Phenotypes of circulating B cells were characterized by flow cytometry. Intrapulmonary processes were evaluated by immunohistochemistry. Plasma B lymphocyte stimulating factor (BLyS) was assayed by ELISA. Circulating B cells of IPF subjects were more Ag differentiated, with greater plasmablast proportions (3.1 +/- 0.8%) than in normal controls (1.3 +/- 0.3%) (p < 0.03), and the extent of this differentiation correlated with IPF patient lung volumes (r = 0.44, p < 0.03). CD20(+) B cell aggregates, diffuse parenchymal and perivascular immune complexes, and complement depositions were all prevalent in IPF lungs, but much less prominent or absent in normal lungs. Plasma concentrations of BLyS, an obligate factor for B cell survival and differentiation, were significantly greater (p < 0.0001) in 110 IPF (2.05 +/- 0.05 ng/ml) than among 53 normal (1.40 +/- 0.04 ng/ml) and 90 chronic obstructive pulmonary disease subjects (1.59 +/- 0.05 ng/ml). BLyS levels were uniquely correlated among IPF patients with pulmonary artery pressures (r = 0.58, p < 0.0001). The 25% of IPF subjects with the greatest BLyS values also had diminished 1-y survival (46 +/- 11%), compared with those with lesser BLyS concentrations (81 +/- 5%) (hazard ratio = 4.0, 95% confidence interval = 1.8-8.7, p = 0.0002). Abnormalities of B cells and BLyS are common in IPF patients, and highly associated with disease manifestations and patient outcomes. These findings have implications regarding IPF pathogenesis and illuminate the potential for novel treatment regimens that specifically target B cells in patients with this lung disease.
引用
收藏
页码:2089 / 2095
页数:7
相关论文
共 50 条
[1]   Lymphoid neogenesis in chronic inflammatory diseases [J].
Aloisi, F ;
Pujol-Borrell, R .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (03) :205-217
[2]   Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].
Anolik, JH ;
Barnard, J ;
Cappione, A ;
Pugh-Bernard, AE ;
Felgar, RE ;
Looney, RJ ;
Sanz, I .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590
[3]   Radiographic Emphysema Predicts Low Bone Mineral Density in a Tobacco-exposed Cohort [J].
Bon, Jessica ;
Fuhrman, Carl R. ;
Weissfeld, Joel L. ;
Duncan, Steven R. ;
Branch, Robert A. ;
Chang, Chung-Chou H. ;
Zhang, Yingze ;
Leader, Joseph K. ;
Gur, David ;
Greenspan, Susan L. ;
Sciurba, Frank C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (07) :885-890
[4]   Idiopathic Pulmonary Fibrosis-an Epidemiological and Pathological Review [J].
Borchers, Andrea T. ;
Chang, Christopher ;
Keen, Carl L. ;
Gershwin, M. Eric .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2011, 40 (02) :117-134
[5]   Rituximab therapy in autoimmune pulmonary alveolar proteinosis [J].
Borie, R. ;
Debray, M-P. ;
Laine, C. ;
Aubier, M. ;
Crestani, B. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (06) :1503-1506
[6]   BAFF, APRIL and their receptors: Structure, function and signaling [J].
Bossen, Claudia ;
Schneider, Pascal .
SEMINARS IN IMMUNOLOGY, 2006, 18 (05) :263-275
[7]   B cells move to centre stage: novel opportunities for autoimmune disease treatment [J].
Browning, Jeffrey L. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (07) :564-576
[8]   IMMUNOHISTOLOGICAL ANALYSIS OF LUNG-TISSUE FROM PATIENTS WITH CRYPTOGENIC FIBROSING ALVEOLITIS SUGGESTING LOCAL EXPRESSION OF IMMUNE HYPERSENSITIVITY [J].
CAMPBELL, DA ;
POULTER, LW ;
JANOSSY, G ;
DUBOIS, RM .
THORAX, 1985, 40 (06) :405-411
[9]   The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus [J].
Cancro, Michael P. ;
D'Cruz, David P. ;
Khamashta, Munther A. .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (05) :1066-1073
[10]  
DALL'AGLIO P P, 1988, Respiration, V54, P36